Jorge Alsina‐Fernandez
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Regulation of Appetite and Obesity, Receptor Mechanisms and Signaling, Pharmacology and Obesity Treatment
Most-Cited Works
- → LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept(2018)781 cited
- → The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL(2017)634 cited
- → Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation(2018)224 cited
- → GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice(2021)209 cited
- → GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models(2021)169 cited
- → Structural determinants of dual incretin receptor agonism by tirzepatide(2022)107 cited
- → GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior(2022)61 cited
- → Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin(2012)54 cited
- → Central Injection of the Stable Somatostatin Analog ODT8-SST Induces a Somatostatin2 Receptor-Mediated Orexigenic Effect: Role of Neuropeptide Y and Opioid Signaling Pathways in Rats(2010)51 cited
- → Long-Acting and Selective Oxytocin Peptide Analogs Show Antidiabetic and Antiobesity Effects in Male Mice(2019)33 cited